I wish there were some link to the study in the article, I tried to find it in the original Financial Times article but I got paywalled. This is really awesome though, I hope further research is shown because I’d love to hear more about how this differs from the previous methods of addressing Alzheimer’s.
I guess
Both lecanemab and donanemab are based on antibodies against amyloid, one of the toxic proteins that build up in the brain as Alzheimer’s proceeds, but they worked at different stages of the process, Oakley said. Lecanemab targets amyloid as it begins to form fibers in the brain while donanemab is active at a later stage, when the fibers have clumped together into larger accumulations of plaque.
Is as close as we’re getting for now haha
Edit: TheOakTree found the study for those who want to read more!
https://jamanetwork.com/journals/jama/fullarticle/2807533
Not exactly what you were looking for (I think) but closer!
From the Ars Article:
The donanemab trial involved 1,736 participants
From your link:
Findings In this randomized clinical trial that included 1736 participants with early symptomatic Alzheimer disease and…
I would be VERY surprised if this wasn’t the study in question 😂
Thank you for finding that! I’ll read that over more when I get some time later!
Now imagine if it were coincidence…
Thankfully it’s not. Happy to see that alzheimer research is getting more interest though, it’s a scary condition.
The article mentions the donanemab study was published in JAMA. A little bit of Googling retrieved this:
Yup, you’re an hour late to that convo haha
I’ll edit my original comment so others see that though.
Weird, that comment definitely wasn’t visible to me when I replied. Must be the magic of federation…
Oh yeah, because you’re both from different instances. I didn’t think about that, we’re all still learning lol
extremely promising! awesome to see
Finally some good fucking news. Wish we had the article, though.
Here you go: https://archive.is/m0mAI
